CN106520598A - Lactobacillus rhamnosus and application - Google Patents
Lactobacillus rhamnosus and application Download PDFInfo
- Publication number
- CN106520598A CN106520598A CN201610937698.9A CN201610937698A CN106520598A CN 106520598 A CN106520598 A CN 106520598A CN 201610937698 A CN201610937698 A CN 201610937698A CN 106520598 A CN106520598 A CN 106520598A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- lactobacillus rhamnosus
- culture
- rhamnosuss
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 52
- 101100207371 Curvularia clavata TR08 gene Proteins 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 14
- 208000004232 Enteritis Diseases 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 3
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 208000018556 stomach disease Diseases 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 208000002551 irritable bowel syndrome Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 8
- 239000012531 culture fluid Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 206010009900 Colitis ulcerative Diseases 0.000 description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229960002433 cysteine Drugs 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 5
- 101100207366 Curvularia clavata TR02 gene Proteins 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 230000007365 immunoregulation Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
- 229960004963 mesalazine Drugs 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000001408 fungistatic effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000001393 triammonium citrate Substances 0.000 description 2
- 235000011046 triammonium citrate Nutrition 0.000 description 2
- 238000007817 turbidimetric assay Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- -1 phosphoric acid hydrogen Chemical class 0.000 description 1
- 230000005622 photoelectricity Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses lactobacillus rhamnosus. The classification name is lactobacillus rhamnosus TR08; and the lactobacillus rhamnosus is collected in China Center for Type Culture Collection (CCTCC), the collection number is CCTCC NO.M 2016548, and the collection date is October 10, 2016. The invention further discloses application of the lactobacillus rhamnosus to preparation of medicines for preparing stomach and intestine diseases.
Description
Technical field
The invention belongs to microbial technology field, more particularly to a kind of lactobacillus rhamnosuss and its preparing treatment gastrointestinal tract
Application in the medicine of disease.
Background technology
Ulcerative colitiss (UC), cryptitiss and sieve engler's disease are the main Types of inflammatory bowel (IBD), the inflammatory bowel
Disease is characterised by the chronic inflammatory disease in intestinal.Clinical symptoms be suffer from diarrhoea, suffer from abdominal pain, occasionality hemorrhage of rectum, lose weight, it is tired and
Sometimes generate heat.Although can occur at any age, IBD is most commonly in the adult of teenager and youth, so these people can
The development that can be postponed and dwarfing grow.Data shows that annual U.S. UC prevalences are 2,00/,100,000 people, treat the flower of UC
Take at 1 to 1.5 hundred million dollar or so, by the end of 2012, UC patient populations were 2.5 times in 2000, and relapse rate is up to 72%；Closely
The number of patients of Nian Lai China UC is in obvious ascendant trend.
Medically, by reducing inflammation and thereby controlling gastrointestinal tract symptom treating IBD.But, at present still can not be
Medically cure IBD.The Clinical course of IBD has very big difference, with patient slightly to moderate symptom without the need for hospitalization, but
It is that the patient of 10-15% can occur the serious process of the disease, and which is followed by surgical operation, colectomy in many cases
Art can eliminate UC, but can reduce quality of life and increase the risk of complication.
Medicine for treating IBS has been popularized, although their effect in clinical trial are little, and
Their Clinical practicability is limited by adverse side effect, and available medicine includes：Using 5- aminosalicylic acid (5-
ASA), corticosteroid and immunoregulation medicament.5-ASA is usually used carries out the slight long-term treatment to moderate IBD symptom, and
Corticosteroid and immunoregulation medicament are used for treating serious symptom；Diarrhoea or stomachache go out as the side effect of 5-ASA
It is existing, and the life-time service Jing of corticosteroid often shows serious side effect, including sclerotin mitigation, infection, diabetes, muscle
Become thin and psychiatric disturbance；Immunoregulation medicament can suppress immune system, and this can control IBD symptoms.But, the immunity of generation
Impaired state can make patient susceptible's numerous disease.Serotonergic medicament has shown the effect of the overall symptom to IBS,
But, their application has seriously been limited with regard to the worry of safety recently.
Probiotic bacteria is defined as that " microorganism living, which can be played beyond intrinsic basis after taking in given number
Health benefits beyond nutrition " (Araya M. et al., 2002；Guarner F. et al., 1998).From the several of Bifidobacterium
It is probiotic bacteria to plant lactic acid bacteria and kind, this hint, it has already been proven that they can promote specific health effect.Probiotic bacteria must is fulfilled for
The several requirements relevant with no toxicity, viability, attachment and beneficial effect.However, existing probiotic bacteria is to treating enteritis effect
It is not good.
The content of the invention
Goal of the invention：The first object of the present invention is to provide a kind of lactobacillus rhamnosuss.
The second object of the present invention is to provide a kind of lactobacillus rhamnosuss in the medicine for preparing treatment gastroenteropathy
Application.
The third object of the present invention is the application for providing a kind of lactobacillus rhamnosuss in the medicine for preparing treatment enteritis.
Technical scheme：In order to solve above-mentioned technical problem, the technical solution adopted in the present invention is：A kind of rhamnose breast bar
Bacterium, its Classification And Nomenclature are lactobacillus rhamnosuss (Lactobacillus rhamnosus) TR08, in China typical culture collection
Center (abbreviation CCTCC) preservation, depositary institution address：Wuhan City, Hubei Province Wuchang District Wuhan University, postcode is 430072,
Its deposit number is：CCTCC NO.M 2016548, preservation date are on October 10th, 2016.
The physiologically active feature of lactobacillus rhamnosuss (Lactobacillus rhamnosus) TR08 is as follows：
Lactobacillus rhamnosuss (Lactobacillus rhamnosus) TR08 on MRS culture medium flat plates bacterium colony compared with
Little, milky, diameter 1-2mm, surface are smoothed, and edge is relatively regular.
Lactobacillus rhamnosuss (Lactobacillus rhamnosus) the TR08 thalline are shaft-like, Gram’s staining sun
Property, spore is not formed, lactic acid, amphimicrobian is produced.
The 16SrDNA sequences of lactobacillus rhamnosuss are as shown in SEQ ID No.1.Surveyed 16SrDNA sequences are passed through into BLAST
Compare, be identified as lactobacillus rhamnosuss (Lactobacillus rhamnosus).
Described lactobacillus rhamnosuss (Lactobacillus rhamnosus) TR08 is answering in antibacterials are prepared
With.
Described lactobacillus rhamnosuss (Lactobacillus rhamnosus) TR08 is to prepare treatment gastroenteropathy
Medicine in application.
Described lactobacillus rhamnosuss (Lactobacillus rhamnosus) TR08 is in the medicine for preparing treatment enteritis
In application.
Have particular application as：Lactobacillus rhamnosuss (Lactobacillus rhamnosus) TR08 is inoculated in into fermentation culture
In base, in 35-39 DEG C of bottom fermentation culture 8-16 hour, the fermentation liquid for obtaining is used as applying microbial inoculum.
The formula of heretofore described fermentation medium is：1000mL distilled water, peptone 10g, glucose 20g, yeast
Powder 9g, sodium acetate 5g, dipotassium hydrogen phosphate 2g, Triammonium citrate 2g, cysteine 0.5g, magnesium sulfate 0.2g, manganese sulfate 0.05g,
Tween 1ml, pH5.5-6.5.
Beneficial effect：Compared with prior art, it is an advantage of the invention that：
(1) lactobacillus rhamnosuss (Lactobacillus rhamnosus) TR08 that the present invention is provided is to various pathogen
It is inhibited；Model of action variation to pathogen；Reproduction speed is fast；Being capable of artificial culture, it is easy to operate, it is easy to life
Produce application；The advantages of high-output stress-resistance.
Lactobacillus rhamnosuss (Lactobacillus rhamnosus) TR08 condition of culture that (2) present invention is provided is simple,
Fermentation time is short, easy preservation, is suitable to industrialized production, with good development prospect.
Description of the drawings
Bacterium colony figures of the Fig. 1 for lactobacillus rhamnosuss (Lactobacillus rhamnosus) TR08.
Bacterium colony enlarged drawings of the Fig. 2 for lactobacillus rhamnosuss (Lactobacillus rhamnosus) TR08.
Fig. 3 is strain first batch Evaluation of Functional growth curve.
Fig. 4 is strain second lot Evaluation of Functional growth curve.
Fig. 5 is the acidproof experimental result picture of bacterial strain.
Fig. 6 is the weight relation curve of lactobacillus rhamnosuss quantity and enteritis mice.
Fig. 7 is the colon lengths relation curve of lactobacillus rhamnosuss quantity and enteritis mice.
Fig. 8 is enteritis mice slice map before and after treatment.
Fig. 9 is lactobacillus rhamnosuss TR08 and Candida albicanss culture fluid culture fungistatic effect figure.
Specific embodiment
Lactobacillus rhamnosuss of the present invention (Lactobacillus rhamnosus) TR08 is elaborated with reference to experimental example
Application.
The separation of 1 bacterial strain of embodiment
1st, strain and culture medium and condition of culture
(1) bacterium source
From certain military region health soldier's feces of China
(2) culture medium
Plating medium：1000mL distilled water, peptone 10g, glucose 20g, yeast powder 9g, sodium acetate 5g, phosphoric acid hydrogen
Dipotassium 2g, Triammonium citrate 2g, cysteine 0.5g, magnesium sulfate 0.2g, manganese sulfate 0.05g, tween 1ml, agar powder 15-20g,
pH5.5-6.5。
2nd, the separation and identification of bacterial strain
(1) separation of bacterial strain
Proper amount of fresh feces are taken in glove box after sterilized process in advance and is placed in the aseptic examination for being loaded with aseptic culture medium
Guan Zhong, fully shaking are vortexed and mix；
The feces solution for mixing is vortexed as stock solution with above-mentioned fully shaking, ten times of gradient dilutions is done to suitable gradient, is taken 100
μ l are spread evenly across in MRS+0.05% cysteine solid plate culture medium, are subsequently taken out and are placed in anaerobic jar, 37 DEG C of anaerobism
Overnight incubation.
On next day visible flat board, length has the bacterium colony of form different sizes, with reference to lactobacilluss colonies typical morphological characteristic, picking
Some representational bacterium colonies make secondary line purification process, and flat board anaerobism activates 1 day, obtains culture, subsequently do identification of strains.
(2) identification of bacterial strain
Gram’s staining Morphological Identification：
A, smear：Sterilized microscope slide is taken in laboratory table, is marked with marking pen on slide, be easy to observation, with
Afterwards slide is inverted, and then 10 μ l physiological saline solution is drawn with pipettor and is uniformly coated at mark, is chosen with liquid-transfering gun then
Take pure culture to be uniformly dissolved in normal saline, coated face is unsuitable excessive.
B, drying：Specimen is faced upwards, the both sides of hand-held microscope slide one end, carefully on alcohol burner, eminence adds slightly
Heat, makes moisture evaporation, but be sure not it is long against flame or heat time heating time, in case specimen is baked withered and is deformed.
C, fixation：It is fixed usually to utilize high temperature, one end of hand-held microscope slide, specimen upwards, at the alcohol burner flame as early as possible
Back and forth through 2-3 time, altogether about 2-3 second kinds, and touch skin with the heating of the microscope slide back side frequently unconsciously are scalded to be advisable excessively and (are not surpassed
Cross 60 DEG C), place after cold, dyeed.
D, just dye：The Deca ammonium oxalate crystal violet 1-2 drops on smear thin film, make dyeing liquor cover smear, dye about 1min.
E, washing：Tilting microscope slide, is rinsed with shallow bid current under water tap, until the water under washing in colourless is
Only.
F, mordant dyeing：About 300ul iodine solutions are drawn with 100-1000ul liquid-transfering guns to drop on smear thin film, is covered dyeing liquor and is applied
Piece, dyes about 1min.
G, washing：Tilting microscope slide, is rinsed with shallow bid current under water tap, until the water under washing in colourless is
Only.
H, decolouring：Tilting microscope slide, 95% ethanol decolorization of Deca, not showing purple to the ethanol for flowing out, about take
20-30S, is washed immediately.
I, redye：The Deca husky of common dye dye liquor 1-2 drops on smear thin film, make dyeing liquor cover smear, dye about 1min.
J, washing：Tilting microscope slide, is rinsed with shallow bid current under water tap, until the water under washing in colourless is
Only.
K, drying, observation：Water droplet is sopped up with absorbent paper, treats that sample slice is done under rearmounted microscope, use low power sem observation, found
Immersion oil being dripped after purpose thing on slide, the form and color of antibacterial being observed with oil mirror, purple is gram positive bacteria, red
Color is gram negative bacteria.
As a result show：The bacterial strain is gram positive bacteria.
The measure of 16S rRNA sequences：
The PCR primers that use of amplification of 16S rRNA genes be general antibacterial primer 8F (5 '-
CACGGATCCAGAGTTTGAT (C/T) (A/C) TGGCTCAG-3 ') and 1510R (5 '-GTGAAGCTTAGGG (C/T)
TACCTTGTTACGACTT-3 ') product entrusts qualified third party's laboratory to carry out sanger sequencings.Using BLAST algorithm
Sequence and 16S rRNA genes are compared in GenBank data bases, adjacent tree is set up using 4.0 programs of MEGA.
BLAST analysis shows TR02 bacterium are sufficiently close to lactobacillus rhamnosuss (99% affinity).
Embodiment 2
(1) strain Evaluation of Functional
A. the measure of growth curve and each monitoring point pH value
1. labelling
Take 11 aseptic Boiling tubes, with marking pen indicate respectively incubation time, i.e., 0,2,4,6,8,24h.
2. it is inoculated with
Proceeded to 5mL aseptic straws absorption 2.5mL TR02 incubated overnight liquid (culture 8-16h) respectively and fill 50mLMRS+
In the triangular flask of 0.05% cysteine culture fluid, 11 nothings that 5mL mixed liquors are put into above-mentioned labelling after mix homogeneously, are taken respectively
In bacterium Boiling tube.
3. cultivate
Vaccinated test tube is put into quiescent culture in 37 DEG C of incubators, 0,2,4,6,8,24 are cultivated respectively, will be indicated corresponding
The test tube of time takes out, and stores in putting refrigerator immediately, and last is with its optical density value of turbidimetric assay.
4. turbidimetric assay
Make blank with nonvaccinated MRS+0.05% cysteine culture medium, photoelectricity ratio is carried out from 600nm wavelength
Turbid measure, starts sequentially determining from the early culture fluid for taking out, the culture fluid MRS+0.05% cysteine big to cell density
Fluid medium is determined after suitably diluting so as to which optical density value is again within 0.1～0.65 (before determining OD values, by training to be determined
Nutrient solution vibrates, and is uniformly distributed cell).
The measure of 5.pH values
Remaining culture liq determines pH value.
B. ascites
1. prepared by bacteria suspension
Culture fluid is made by the appropriate bacteria suspension of concentration with physiological saline solution.
2. microscopy studio
Before sample-adding, microscopy is carried out to the studio of counting chamber first, if there is dirt, need cleaning, can just carry out after drying up
Count.
3. product are loaded
By cleaning dry blood cell counting plate covered, then with aseptic capillary burette by the culture fluid for shaking up by
Coverslip edge drips a droplet, allows bacterium solution to lean on capillary osmosis automatically into studio along gap, and general technology room can be filled
Full bacterium solution.
Bacterium solution will be first shaken up during sampling；During sample-adding, studio can not have bubble to produce.
4. microscopic counting
Static 5min after sample-adding, is then placed in blood cell counting plate on microscope carrier, first finds skill with low power lens
Art room position, then changes high power lenses into and is counted.
The power for adjusting microscope light is appropriate, should not be partial to one for being also noted that with the microscope of illuminator daylighting
It is difficult to see studio's grid line in side, the otherwise visual field, or only sees vertical line or only see horizontal line.
If finding before counting, bacterium solution is too dense or too dilute, counts after need to readjusting dilution factor, general sample dilution again
It is required that 5～10 thalline are there are about in per little lattice is advisable.Each studio selects 5 middle lattice (in optional 4 angles and central one
Lattice) in thalline counted.Above the general number of elements of thalline on ruling and on right side bearing.Counting sample will be from
The meansigma methodss that Liang Ge studios fall into a trap are calculating the bacteria containing amount of sample.
5. blood cell counting plate is cleaned
After finishing, blood cell counting plate is rinsed well with water on faucet, be sure not to be scrubbed with hard thing, after washing
Voluntarily dry or dried up with hair-dryer.Microscopy, whether observation is interior per little lattice residual thalline or other precipitate.If unclean,
Then necessary repeated washing is to clean.
Two batch strain Evaluation of Functional result collimations are preferable (being shown in Table 1, table 2, Fig. 3 and Fig. 4), growth curve result table
Bright TR02 bacterium are in 0～4h in laundering period, 4～8h and are in exponential phase, and 8～12h is in plateau, enters after 12h
Enter phase of decline；With growth curve in both diametrically opposite situation, culture terminal pH is 4.44 to pH curves.
Terminal culture fluid Jing microscopic counts result is 3.54 × 108cfu/ml。
1 batch of table, one strain Evaluation of Functional
2 batch of table, two strain Evaluation of Functional
(2) the acidproof experiment of bacterial strain
Strains tested is inoculated in MRS+0.05% cysteine hydrochloride fluid mediums, activation culture 24h, with
5% inoculum concentration is added to two parts with (it is blank that pH is 6.2 culture medium in the MRS culture medium that hydrochloric acid tune pH is 2.5 and 6.2
Control), first part is used sterile saline gradient dilution, is taken 100 μ L of diluent and is inoculated into MRS flat board coated plates, is placed in 37 DEG C, training
Foster 48h, carries out colony counting.After second part 37 DEG C process 3h, then sterile saline gradient dilution is used, take 100 μ L of diluent
MRS flat board coated plates are inoculated into, 37 DEG C of culture 48h are placed in, are carried out the viable count of colony counting, i.e. 3h, and calculate lactic acid bacteria
Survival rate.Survival rate (%)=(viable count of the viable count/0h of 3h) × 100.
3h is cultivated under pH6.5 and pH4.5 environment from table 3 and Fig. 5, TR02 and has no appreciable impact, and in pH3.0 bars
Growth under part is affected, and shows that TR02 can be tolerated under pH4.5 environment.
3 bacterial strain acid resistance test result of table
3 experiment in vivo of embodiment
1. the induction of colitis and treatment
With feeding C57BL/6 type mices of the solution containing 2.5%DSS (molecular weight 36-50KDa) (1-7 days), to induce colon
Scorching model mice；Matched group then feeds water.In subsequent 10 days, the oral water of difference, lactic acid bacteria (embedding 0.9*109、1.2*
109、2.4*109, do not embed 2.4*109) and willow nitrogen Huang amine pyridine (0.5g/kg).
Weigh in daily, in observation stool in mice viscosity and feces and at anus, whether have blood.Calculate disease activity
Index (DAI).In short, being calculated by following parameter：
A) diarrhoea (0 point=normal, 2 points=light feces, 4 points=watery diarrhea)；
B) blood courage (0 point=no bleeding, 2, slight bleeding, 4 points, massive hemorrhage).
The 10th day after inducing colitis, animal is put to death, take out colon, and colon's piece is prepared for analyzing in vitro.
It is in order to carry out histologic analysis, a part for colon is fixed in 10% formalin, and be embedded in paraffin.According to mark
H＆E is to section statining for quasi-project.
The Histological evaluation of the section of colon of H＆E dyeing is classified as follows：0, NIP sign；1. low leukocyte infiltration；2.
Moderate leukocyte infiltration；3. high leukocytic infiltration, moderate fibrosis, high vessel density, colon wall thickening, moderate goblet cell are damaged
Become estranged the focal loss and 4. transmurals infiltration of crypts, a large amount of losses of goblet cell, the diffusivity of extensive fibrosiss and crypts
Loss.Histological score is carried out by pathologist.
It is from Fig. 6,7,8, as the increase of lactic acid bacterium number improves significantly to the body weight of enteritis mice, right
The colon lengths of enteritis mice improve significantly, and enteritis mice is compared with the section of normal mouse, and goblet cell is gradually
Reduce, inflammatory cell gradually increases.
2. bacteriostasis efficacy
Lactobacillus rhamnosuss TR08 is cultivated respectively and is mixed with Candida albicanss culture fluid, respectively determine 0,6,9,
12nd, the OD values and pH value of 24h, as shown in figure 9, lactobacillus rhamnosuss TR08 has obvious fungistatic effect, and energy to Candida albicanss
The pH value of environment is reduced substantially.
SEQUENCE LISTING
<110>Its beneficial health science academy（Zhenjiang）Company limited
<120>A kind of lactobacillus rhamnosuss and its application
<130> SC20161008002
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 1474
<212> DNA
<213> Lactobacillus rhamnosus
<220>
<221> misc_feature
<222> (1)..(1474)
<400> 1
cgctggcggc gtgcctaata catgcaagtc gaacgagttc tgattattga aaggtgcttg 60
catcttgatt taattttgaa cgaatggcgg aagggtgaat aacccgtggg taacctggcc 120
ttaaatgggg gataaccttt ggaaaccgaa gctaataccg cataaatccc aaaaccgcat 180
ggttcttggc tgaaagatgg ggtaaactat cccttttgga tggacccccg gcgtattaac 240
ttgttggtga ggtaacggct ccaccaggga atgataccta acccaactga aaggttgatc 300
ggccaccttg ggactgagac ccggcccaaa ctcctaccgg agggagcaat agggaatctt 360
ccccaatgga cgccagtctg aaggaacaac cccccgtggg tgaaaaaggg tttccggtcc 420
taaaactctg ttgttggaaa aaaatggtcc gcaaaataac tggtggccgc gtggccgtat 480
ccaacccgaa agccacggct aactacctgc ccagcaccgc ggtaataccg aggtggcaag 540
cgttatccgg atttattggg cgtaaagcga gcgcaagcgg gttttttagt ctgatgggaa 600
agccctcggc ttaaccgaag aagtgcatcg gaaactggga aacttgaatg cagaagaaga 660
cagtggaact ccatgtgtag cggtgaaatg cctagatata tggaagaaca ccagtggcga 720
aagccgctgt ctggtctgta actgacgctg aagctccaaa gcctgggtag cgaacaggat 780
tagataccct gggagtccat gccgtaacga tgaatgctag tggtggaagg tttccgccct 840
tcaatgccga gcttacgcaa taagcaatcc gcctggggga atacgaccgg caggttgaaa 900
cttcaaagaa tttgaccggg gccgcacaag ccggtggagc attgtggttt aattcgaagc 960
acgcgaagaa cttaccaggt cttgacatct tttgatcact tgaagatcaa gtttcccttc 1020
gggcaaatga cagtggtgca tggttgtcgt cagctccgtg tcgtgagatg ttgggttaag 1080
tcccgcaacg agcgcaaccc ttatgactag ttgccagcat ttagttgggc actctagtaa 1140
gactgccggt gacaaaccgg aggaaggtgg ggatgacgtc aaatcatcat gccccttatg 1200
acctgggcta cacacgtgct acaatggatg gtacaacgag ttgcgagacc gcgaggtcaa 1260
gctaatctct taaagccatt ctcagttcgg actgtaggct gcaactcgcc tacacgaagt 1320
cggaatcgct agtaatcgcg gatcagcacg ccgcggtgaa tacgttcccg ggccttgtac 1380
acaccgcccg tcacaccatg agagtttgta acacccgaag ccggtggcgt aaccctttta 1440
gggagcgagc cgtctaaggt ggacaaatga tact 1474
Claims (4)
1. a kind of lactobacillus rhamnosuss（Lactobacillus rhamnosus）TR08, is deposited in China typical culture collection
Center, deposit number is：CCTCC NO.M 2016548, preservation date are on October 10th, 2016.
2. application of the lactobacillus rhamnosuss described in claim 1 in antibacterials are prepared.
3. application of the lactobacillus rhamnosuss described in claim 1 in the medicine for preparing treatment gastroenteropathy.
4. application of the lactobacillus rhamnosuss described in claim 1 in the medicine for preparing treatment enteritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610937698.9A CN106520598A (en) | 2016-10-25 | 2016-10-25 | Lactobacillus rhamnosus and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610937698.9A CN106520598A (en) | 2016-10-25 | 2016-10-25 | Lactobacillus rhamnosus and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106520598A true CN106520598A (en) | 2017-03-22 |
Family
ID=58292670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610937698.9A Pending CN106520598A (en) | 2016-10-25 | 2016-10-25 | Lactobacillus rhamnosus and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106520598A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107217022A (en) * | 2017-07-18 | 2017-09-29 | 邓禹 | One plant of Lactobacillus rhamnosus and its application |
| CN107494964A (en) * | 2017-06-14 | 2017-12-22 | 镇江市天益生物科技有限公司 | A kind of probiotic composition and its application |
| CN109662976A (en) * | 2019-02-14 | 2019-04-23 | 西南大学 | A kind of application of Lactobacillus rhamnosus in the health food and drug of preparation prevention ulcerative colitis |
| CN110122877A (en) * | 2018-02-09 | 2019-08-16 | 深圳市华大农业应用研究院 | Lactobacillus rhamnosus and application thereof |
| CN114672441A (en) * | 2022-05-05 | 2022-06-28 | 华中农业大学 | Lactic acid bacteria composition and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101671634A (en) * | 2009-09-30 | 2010-03-17 | 湖南农业大学 | Rhamnose lactobacillus M8, rhamnose lactobacillus SLP and preparation method thereof |
| CN103421715A (en) * | 2013-08-03 | 2013-12-04 | 青岛蔚蓝生物集团有限公司 | Lactobacillus rhamnosus and application thereof |
| CN103937708A (en) * | 2014-03-24 | 2014-07-23 | 华东理工大学 | Lactobacillus rhamnosus and its application |
| CN104365863A (en) * | 2014-09-28 | 2015-02-25 | 中国农业大学 | Lactobacillus rhamnosus, its application, cheese, and preparation method of cheese |
| CN105624069A (en) * | 2016-03-14 | 2016-06-01 | 青岛东海药业有限公司 | Lactobacillus rhamnosus preparation and application thereof |
-
2016
- 2016-10-25 CN CN201610937698.9A patent/CN106520598A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101671634A (en) * | 2009-09-30 | 2010-03-17 | 湖南农业大学 | Rhamnose lactobacillus M8, rhamnose lactobacillus SLP and preparation method thereof |
| CN103421715A (en) * | 2013-08-03 | 2013-12-04 | 青岛蔚蓝生物集团有限公司 | Lactobacillus rhamnosus and application thereof |
| CN103937708A (en) * | 2014-03-24 | 2014-07-23 | 华东理工大学 | Lactobacillus rhamnosus and its application |
| CN104365863A (en) * | 2014-09-28 | 2015-02-25 | 中国农业大学 | Lactobacillus rhamnosus, its application, cheese, and preparation method of cheese |
| CN105624069A (en) * | 2016-03-14 | 2016-06-01 | 青岛东海药业有限公司 | Lactobacillus rhamnosus preparation and application thereof |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107494964A (en) * | 2017-06-14 | 2017-12-22 | 镇江市天益生物科技有限公司 | A kind of probiotic composition and its application |
| CN107217022A (en) * | 2017-07-18 | 2017-09-29 | 邓禹 | One plant of Lactobacillus rhamnosus and its application |
| CN110122877A (en) * | 2018-02-09 | 2019-08-16 | 深圳市华大农业应用研究院 | Lactobacillus rhamnosus and application thereof |
| CN110122877B (en) * | 2018-02-09 | 2022-12-23 | 深圳华大基因农业控股有限公司 | Lactobacillus rhamnosus and application thereof |
| CN109662976A (en) * | 2019-02-14 | 2019-04-23 | 西南大学 | A kind of application of Lactobacillus rhamnosus in the health food and drug of preparation prevention ulcerative colitis |
| CN109662976B (en) * | 2019-02-14 | 2023-08-08 | 西南大学 | Application of lactobacillus rhamnosus in preparation of medicine for preventing ulcerative colitis |
| CN114672441A (en) * | 2022-05-05 | 2022-06-28 | 华中农业大学 | Lactic acid bacteria composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106520598A (en) | Lactobacillus rhamnosus and application | |
| CN106520599A (en) | Lactobacillus reuteri and applications | |
| CN106011036B (en) | One plant of bacillus coagulans HEW-B379 and its application with prebiotic effect | |
| CN104630083B (en) | A kind of Lactobacillus crispatus and its application in feminine care products | |
| CN110317757B (en) | Lactobacillus plantarum HJ-S2 with cholesterol-reducing and selenium-rich effects and application thereof | |
| CN108004187A (en) | A kind of lactobacillus gasseri and its application for being used to prepare vagina antibacterial medicines | |
| CN106754470A (en) | The Lactobacillus rhamnosus in one plant of lacto source and its application | |
| CN112094785B (en) | Bifidobacterium animalis as well as preparation and application thereof | |
| CN111925961B (en) | Lactobacillus plantarum Lp2 and application thereof | |
| CN101314763A (en) | Short bifidobacteria with functions of anti-gastrointestinal tract pathogen, oxidation resistance and blood pressure reduction | |
| CN110669690B (en) | Lactobacillus plantarum strain for expressing quorum sensing signal molecule AI-2 and application thereof | |
| CN103911306B (en) | Lactobacillus gasseri bacterial strain and application thereof | |
| CN106497808A (en) | One plant of Lactobacillus salivarius that can be used to produce fermented feed for being isolated from Intestinum Sus domestica road | |
| CN114806978B (en) | Lactobacillus johnsonii SXDT-23 and application thereof | |
| CN116656534B (en) | Bifidobacterium longum subspecies capable of improving exercise capacity and application thereof | |
| CN109266584A (en) | One plant of cilium type Lactobacillus rhamnosus and application thereof with mast cell activity adjustment effect | |
| CN106509913A (en) | Composition for regulating balance of intestinal flora | |
| CN112175872B (en) | Lactobacillus rhamnosus and preparation and application thereof | |
| CN104818230A (en) | Lactobacillus plantarum L01 having cholesterol degrading function and application thereof | |
| CN111040959B (en) | Grass carp source lactic acid bacteria with specific pathogenic microorganism antagonistic capability and application thereof | |
| CN106834197B (en) | A kind of abductive approach of lactobacillus VBNC state | |
| CN103911309B (en) | Lactobacillus gasseri bacterial strain and application thereof | |
| CN104877940B (en) | One plant of streptococcus thermophilus | |
| CN105112334B (en) | Probiotics containing lactobacillus plantarum | |
| CN102021131B (en) | Bacillus licheniformis strain and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |